Detalhe da pesquisa
1.
PARP inhibition: A promising therapeutic target in ovarian cancer.
Cell Mol Biol (Noisy-le-grand)
; 61(6): 44-61, 2015 Oct 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-26518896
2.
The treatment with Levonorgestrel Releasing Intrauterine System (LNG-IUS) in patients affected by menometrorrhagia, dysmenorrhea and adenomimyois: clinical and ultrasonographic reports.
Eur Rev Med Pharmacol Sci
; 25(9): 3432-3439, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34002816
3.
Prognostic role of immunohistochemical overexpression of the p16 protein in women under the age of 35 and diagnosed with HSIL (CIN2) subjected to "cervix sparing" excision.
Eur Rev Med Pharmacol Sci
; 25(3): 1261-1273, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33629296
4.
BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).
Eur J Cancer
; 50(12): 2090-8, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24889916
5.
Past, present and future strategies of immunotherapy in gynecological malignancies.
Curr Mol Med
; 13(4): 648-69, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22934850